Syon Capital LLC Acquires 401 Shares of DexCom, Inc. (NASDAQ:DXCM)

Syon Capital LLC lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 9.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,549 shares of the medical device company’s stock after purchasing an additional 401 shares during the quarter. Syon Capital LLC’s holdings in DexCom were worth $564,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Stableford Capital II LLC increased its stake in shares of DexCom by 2.1% in the 4th quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after purchasing an additional 88 shares during the last quarter. Valley National Advisers Inc. increased its position in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after purchasing an additional 103 shares in the last quarter. FORVIS Wealth Advisors LLC increased its position in DexCom by 0.7% during the 4th quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock worth $2,033,000 after purchasing an additional 110 shares in the last quarter. Cary Street Partners Investment Advisory LLC lifted its stake in DexCom by 11.1% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock valued at $108,000 after purchasing an additional 115 shares during the last quarter. Finally, HM Payson & Co. boosted its holdings in shares of DexCom by 8.5% during the 3rd quarter. HM Payson & Co. now owns 1,480 shares of the medical device company’s stock valued at $138,000 after acquiring an additional 116 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on DXCM shares. UBS Group lifted their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Raymond James lifted their target price on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday. Canaccord Genuity Group increased their price target on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday. Citigroup boosted their target price on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, Royal Bank of Canada began coverage on shares of DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $141.67.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the sale, the chief executive officer now owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the transaction, the chief executive officer now owns 333,526 shares in the company, valued at approximately $44,479,027.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares in the company, valued at $5,839,974.37. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 189,375 shares of company stock worth $25,530,859. Insiders own 0.41% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $124.34 on Friday. The stock has a market cap of $49.24 billion, a P/E ratio of 80.22, a P/E/G ratio of 2.37 and a beta of 1.20. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. The company’s 50 day moving average price is $131.13 and its two-hundred day moving average price is $118.30. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.38% and a net margin of 16.82%. The business had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. On average, equities analysts predict that DexCom, Inc. will post 1.76 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.